Anzeige
Meldung des Tages: +45% GAP – und das könnte erst der Anfang sein: FUTR zündet die Neubewertung

Recordati News

Aktie
WKN:  A0EABR ISIN:  IT0003828271 US-Symbol:  RCDTF Branche:  Pharmazeutika Land:  Italien
48,72 €
-0,38 €
-0,77%
10.04.26
Depot/Watchlist
Marktkapitalisierung *
10,04 Mrd. €
Streubesitz
22,23%
KGV
20,78
Dividende
1,30 EUR
Dividendenrendite
2,69%
Nachhaltigkeits-Score
57 %
Index-Zuordnung
-

Recordati News

17.02.26 - GlobeNewswire
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%
Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-​for-like basis (3) at constant exchange rates (CER) EBITDA (1) of € 991.1 million, +14.5%, ...
29.01.26 - GlobeNewswire
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio
11.11.25 - GlobeNewswire
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
NEWS RELEASE
23.10.25 - GlobeNewswire
RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER
NEWS RELEASE
21.10.25 - GlobeNewswire
Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology
The 2026 Award is focused on research in paediatric oncology, specifically sarcomas Paediatric sarcomas are among the leading causes of cancer-​related death in children, yet ...
29.07.25 - GlobeNewswire
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
Consolidated net revenue of € 1,323.8 million in the first half of 2025, +11.7% or +7.8% on a like-​for-like basis ( 3) and at constant exchange rates (CER) EBITDA ( 1) of € 496.3 million, ...
24.06.25 - GlobeNewswire
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA ® IN EUROPE
08.05.25 - GlobeNewswire
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-​for-like basis (3) and at constant exchange rates (CER) EBITDA (1) of € 270.2 million, ...
28.04.25 - GlobeNewswire
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
RECORDATI: 2025-2027 THREE-​YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA (1) BETWEEN € 1,140 AND € 1,225 ...
16.04.25 - GlobeNewswire
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
RECORDATI: FDA GRANTS ISTURISA ® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH ...

Newssuche

Videos

newspaper
07.04.26 -4,86%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »